Paper4875331
Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci.
Okamoto H and 3 others. Jpn J Microbiol, 1967. Cited by 253 papers, by iCite.
Cite this record
ConductScience Library. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Papers, record 4875331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4875331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms, Experimental | Major topic |
| Streptococcus | Major topic |
| Streptolysins | Major topic |
| Animals | |
| Culture Media | |
| Culture Techniques | |
| Neoplasm Transplantation | |
| Penicillins | |
| RNA | |
| Ribonucleases | |
| Streptococcal Infections |
Source PubMed
Cited by52
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 253 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40726887 | Refractory Ranula Following Surgery for Tongue Cancer: A Case Report. | Cureus | 2025 | https://conductscience.org/library/papers/40726887 | PubMed |
| 40692748 | Enhanced efficacy of immune checkpoint inhibitors with OK-432 in malignant pleural mesothelioma: A case report. | Mol Clin Oncol | 2025 | https://conductscience.org/library/papers/40692748 | PubMed |
| 40400941 | Effect of OK-432 pleurodesis on long-term survival outcomes after pulmonary lobectomy for lung cancer patients: a retrospective case-control study. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/40400941 | PubMed |
| 36548729 | Preliminary Exploration of a New Therapy for Interstitial Cystitis/Bladder Pain Syndrome: Botulinum Toxin A Combined with Sapylin. | Toxins (Basel) | 2022 | https://conductscience.org/library/papers/36548729 | PubMed |
| 34209347 | The Soluble Factor from Oral Cancer Cell Lines Inhibits Interferon-γ Production by OK-432 via the CD40/CD40 Ligand Pathway. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34209347 | PubMed |
| 30486312 | OK-432 Administration Inhibits Murine Allergic Rhinitis at the Induction Phase, through the Macrophage Activation with TLR2 Signaling Pathway. | Med Sci (Basel) | 2018 | https://conductscience.org/library/papers/30486312 | PubMed |
| 29730580 | Toll-like receptors in immunity and inflammatory diseases: Past, present, and future. | Int Immunopharmacol | 2018 | https://conductscience.org/library/papers/29730580 | PubMed |
| 29666687 | Efficacy of OK-432 Therapy for the Incisionless Treatment of Head and Neck Cystic Masses: Case series. | Sultan Qaboos Univ Med J | 2018 | https://conductscience.org/library/papers/29666687 | PubMed |
| 27169846 | Experimental validation of talc pleurodesis for carcinomatous pleuritis in an animal model. | Gen Thorac Cardiovasc Surg | 2016 | https://conductscience.org/library/papers/27169846 | PubMed |
| 27141345 | Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. | Oncoimmunology | 2016 | https://conductscience.org/library/papers/27141345 | PubMed |
| 26855819 | Dendritic cell-based vaccine for pancreatic cancer in Japan. | World J Gastrointest Pharmacol Ther | 2016 | https://conductscience.org/library/papers/26855819 | PubMed |
| 26101781 | Harnessing the Microbiome to Enhance Cancer Immunotherapy. | J Immunol Res | 2015 | https://conductscience.org/library/papers/26101781 | PubMed |
| 25804300 | The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials. | Gastric Cancer | 2016 | https://conductscience.org/library/papers/25804300 | PubMed |
| 25537519 | Classification of current anticancer immunotherapies. | Oncotarget | 2014 | https://conductscience.org/library/papers/25537519 | PubMed |
| 25083332 | Trial Watch: Toll-like receptor agonists in oncological indications. | Oncoimmunology | 2014 | https://conductscience.org/library/papers/25083332 | PubMed |
| 24083080 | Trial Watch: Toll-like receptor agonists for cancer therapy. | Oncoimmunology | 2013 | https://conductscience.org/library/papers/24083080 | PubMed |
| 23814492 | Immunochemoradiotherapy for patients with oral squamous cell carcinoma: augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-ray irradiation. | Neoplasia | 2013 | https://conductscience.org/library/papers/23814492 | PubMed |
| 23526132 | Links between Toll-like receptor 4 and breast cancer. | Oncoimmunology | 2013 | https://conductscience.org/library/papers/23526132 | PubMed |
| 23359778 | The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer. | Chin J Cancer Res | 2012 | https://conductscience.org/library/papers/23359778 | PubMed |
| 23300824 | TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors. | PLoS One | 2012 | https://conductscience.org/library/papers/23300824 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4875331
GET https://conductscience.org/api/papers/v1/4875331/cited_by?page=2